Streetbeat News

Regulatory

NICE

Oodle Car Finance has chosen NICE's AI-driven customer experience solutions, including Enlighten AI for Vulnerable Customers, to improve service for vulnerable consumers. NICE's technology provides real-time guidance to contact center agents, ensuring fair treatment and regulatory compliance with the UK's FCA guidelines. The cloud-based applications analyze interactions to identify vulnerability indicators, improving key performance indicators and operational costs. Oodle has already seen improvements in identifying vulnerable customers, and the solution will continue to evolve for better service delivery.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:04 pm

IMMP

Immutep has expanded its INSIGHT-003 Phase I clinical trial to four sites across Germany. This expansion is aimed at facilitating patient enrollment and advancing the trial that evaluates the safety and efficacy of its lead product candidate.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:03 pm

USO

OPEC+ is set to proceed with its meeting on Sunday as scheduled, according to Reuters citing Ria. The outcome of this meeting could influence global oil supply and prices.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:02 pm

GROM

Grom Social Enterprises, Inc. has signed an $8M convertible notes financing agreement with an institutional investor. The deal includes the sale of two convertible promissory notes, each worth $4M, and the issuance of warrants for over 3 million shares. Shareholder approval is required, with closings contingent on this and SEC registration effectiveness. The funds will be used for general working capital and administrative purposes. EF Hutton is the exclusive placement agent for the transaction.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:02 pm

AVXL

Anavex Life Sciences Corp. has been granted a U.S. patent for ANAVEX®2-73 (blarcamesine) for treating insomnia, anxiety, or agitation. The patent, expected to last until at least 2037, covers various dosage forms and complements another patent lasting until 2038. The economic burden of insomnia and anxiety in the U.S. is significant, with costs exceeding $100 billion and $46.4 billion respectively. The patent strengthens Anavex's portfolio for treating CNS disorders, including Alzheimer's and Parkinson's diseases.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:01 pm

EWG

INTC

A German court ruling may lead to Intel losing billions of euros in subsidies for a planned semiconductor factory in Germany. The decision could have significant implications for the company's expansion plans in Europe and its ability to compete globally.

Portfolio Pulse from Charles Gross

November 22, 2023 | 12:37 pm

AAPL

HNHPF

Foxconn Technology Group, a key supplier for Apple Inc, faces increased regulatory scrutiny in China. The Foxconn Industrial Internet Co unit was fined 20,000 yuan for overstating expenses in Wuhan. Chinese authorities are also examining Foxconn's tax affairs and land use in major manufacturing regions. Despite this, Foxconn is expanding in India with over $1.2 billion investment in Karnataka, indicating a shift in production away from China amid regulatory uncertainties.

Portfolio Pulse from Anusuya Lahiri

November 22, 2023 | 12:34 pm

MSFT

Elon Musk, on X (formerly Twitter), expressed his support for OpenAI's semi-independence rather than a merger with Microsoft Corporation (NASDAQ:MSFT). Musk has been critical of Microsoft's significant control over OpenAI, citing concerns over the concentration of power in tech. His comments reflect ongoing concerns about the relationship between OpenAI and Microsoft, including the control over OpenAI's ChatGPT and its operation in Microsoft data centers.

Portfolio Pulse from Benzinga Neuro

November 22, 2023 | 12:30 pm

TRDA

Entrada Therapeutics announced that the FDA has maintained the clinical hold on its Investigational New Drug (IND) application for ENTR-601-44. The FDA declined to lift the hold, which affects the company's ability to proceed with clinical trials for this drug candidate.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 12:06 pm

FEAM

5E Advanced Materials, Inc. has received authorization from the Environmental Protection Agency (EPA), which is a significant regulatory milestone for the company. This authorization likely pertains to the company's operations or products, which could have implications for its business activities and compliance with environmental standards.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 12:01 pm